<div id="readability-page-1"><div>Elsbernd Brian Officer of Catalyst Pharmaceuticals Inc [CPRX] filed a Form 4 on December 10, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:<div><table><tbody><tr><th>Date</th><th>Transaction</th><th>Shares</th><th>Price</th><th>Value</th></tr><tr><td>12/8/25</td><td>Exercise</td><td>7,067</td><td>$0.00</td><td>N/A</td></tr><tr><td>12/8/25</td><td>Surrender(1)</td><td>2,780</td><td>$23.18</td><td>$64,440</td></tr></tbody></table></div>Ending Holdings: 238,457 - Direct<ul><li>(1)</li><li>Surrender of shares back to company to pay option exercise cost and/or resulting tax liability.</li></ul>For a free trial, or to learn more about our insider trading analysis and data services, please visit http://www.washingtonservice.com or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data. </div></div>

CPRX

Officer Brian Elsbernd of Catalyst Pharmaceuticals Inc filed a Form 4 with the SEC, disclosing changes in ownership. On December 8, 2025, he exercised 7,067 shares and surrendered 2,780 shares at $23.18 each to cover option exercise costs and tax liabilities. His ending holdings are 238,457 shares directly. This transaction highlights insider trading activities within the company.

Officer Elsbernd Acquires 4,287 Of Catalyst Pharmaceuticals Inc [CPRX]